Last updated 2 months ago
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
1150 patients around the world
Available in Argentina, United States
Novo Nordisk A/S
6Research sites
1150Patients around the world
This study is for people with
Obesity
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Male or female (sex at birth).Informed consent obtained before any study-related activities.Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.History of at least one self-reported unsuccessful dietary effort to lose body weight.
- HbA1c ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Sites
Centro Médico Maffei - CABA, Buenos Aires
Recruiting
Instituto de Investigaciones Clínicas Córdoba
Recruiting
Instituto de Investigaciones Clínicas San Nicolás
Recruiting
Sanatorio Esperanza
Recruiting
CIPADI - Centro Integral de Prevención y Atención en Diabetes
Recruiting
Fundación Centro de Salud e Investigaciones Médicas (CESIM)
Recruiting
StudyAMAZE 1
SponsorNovo Nordisk A/S
Study typeInterventional
Conditions
Obesity
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07339423
